Byrne Asset Management LLC Sells 193 Shares of Novo Nordisk A/S (NYSE:NVO)

Byrne Asset Management LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,167 shares of the company’s stock after selling 193 shares during the period. Byrne Asset Management LLC’s holdings in Novo Nordisk A/S were worth $358,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S during the third quarter valued at $42,000. Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S during the third quarter valued at $48,000. Dunhill Financial LLC increased its holdings in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares during the last quarter. Finally, Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NVO has been the subject of several recent research reports. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Down 0.9 %

NYSE NVO opened at $86.39 on Friday. The stock has a market cap of $387.66 billion, a PE ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company’s 50-day moving average price is $91.86 and its 200-day moving average price is $111.83.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts forecast that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.